Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20861592 | 0.94 | ERN1 (0.40) | ERN1CHRM2CHRM1CHRNB2CHRM3 | |
| SCHEMBL17397866 | 0.85 | LMNA (0.37) | ERN1MAPK1P2RX7 | |
| SCHEMBL25078221 | 0.82 | P2RX7 (0.35) | MAPK1P2RX7 | |
| SCHEMBL17397902 | 0.80 | LMNA (0.47) | ERN1MAPK1DYRK1ADYRK2DYRK1B | |
| SCHEMBL20861650 | 0.80 | ERN1 (0.34) | ERN1 | |
| SCHEMBL15056617 | 0.78 | MAPK1 (0.34) | ERN1MAPK1P2RX7 | |
| SCHEMBL22802070 | 0.78 | LPL (0.33) | ERN1MAPK1P2RX7 | |
| SCHEMBL31394434 | 0.77 | MAPK1 (0.38) | MAPK1P2RX7 | |
| SCHEMBL17822053 | 0.74 | ERN1 (0.49) | ERN1CHRM2CHRM1CHRNB2CHRM3 | |
| SCHEMBL552698 | 0.72 | ERN1 (0.32) | ERN1MAPK1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3164404-B1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO CO LTD (JP) | 2019-04-03 | — | — | EP | disclosed |
| US-9944660-B2 | Tricyclic benzoxaboroles as antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-9944660-B2 | Tricyclic benzoxaboroles as antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-9944660-B2 | Tricyclic benzoxaboroles as antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-20170174709-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170174709-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170174709-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| EP-3164404-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016001834-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016001834-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174709-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | REN, ALPI, IKBKE | ERN1 907/4885CHRM2 4819/4885CHRM1 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.